Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Cytokinetics, Lowers Price Target to $90

Author: Benzinga Newsdesk | May 23, 2024 01:03pm
HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $94 to $90.

Posted In: CYTK